Explore the words cloud of the GBM-CPP project. It provides you a very rough idea of what is the project "GBM-CPP" about.
The following table provides information about the project.
FUNDACIO PRIVADA INSTITUT D'INVESTIGACIO ONCOLOGICA DE VALL-HEBRON
|Coordinator Country||Spain [ES]|
|Total cost||147˙750 €|
|EC max contribution||147˙750 € (100%)|
1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
|Duration (year-month-day)||from 2016-08-01 to 2017-07-31|
Take a look of project's partnership.
|1||FUNDACIO PRIVADA INSTITUT D'INVESTIGACIO ONCOLOGICA DE VALL-HEBRON||ES (BARCELONA)||coordinator||147˙750.00|
Despite ever-increasing investments in the development of new treatments, many cancers remain incurable. One reason is that most current therapies target redundant functions around which tumour cells can build resistance. We focus instead on a unique and essential cellular function: the Myc oncogene, deregulated in more than 70% of human cancers. Targeting Myc has long been considered unfeasible because of potentially catastrophic side effects. Against this dogma, using a Myc inhibitor called Omomyc, we showed that Myc inhibition displays extraordinary therapeutic benefit in various mouse models of cancer (e.g. lung, brain, pancreas and skin) and causes only mild and reversible side effects. Importantly, no resistance to Omomyc has been observed, and Omomyc constitutes the best Myc inhibitor known to date. Omomyc has so far been used only as a transgene and proof of principle. However, thanks to the ERC-2013-CoG n° 617473, we now have evidence that the Omomyc peptide has cell-penetrating activity, and reaches lung and brain upon nasal administration, where it exerts its anti-tumorigenic activity in cancer cells (data protected by a patent application EP13382167.8). Thus, the Omomyc peptide could become the first clinically viable direct Myc inhibitor to treat lung, brain and other types of cancer.
Our overall project encompasses the preclinical development of the Omomyc peptide to reach Phase I/II clinical trials, at which point the technology will be transferred to a pharmaceutical company for further commercialization. Hence, in this ERC Proof of Concept application, we propose to achieve specific, essential early milestones for the pharmaceutical development of the Omomyc product that will de-risk it and noticeably increase its value and the probability of reaching the market.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "GBM-CPP" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (firstname.lastname@example.org) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "GBM-CPP" are provided by the European Opendata Portal: CORDIS opendata.
Biomineralizing coatings for maxillofacial implantsRead More
Cliodynamic archaeology: Computational approaches to Final Palaeolithic/earliest Mesolithic archaeology and climate changeRead More
The Power of Randomness and Continuity in Submodular OptimizationRead More